|Day Low/High||87.28 / 89.42|
|52 Wk Low/High||75.81 / 100.03|
Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.
Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.
I think M&A activity will pick up markedly going forward across the industry.
Here's what you need to know for Monday, April 9.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.
I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.
Here are how some of the conference presenters are performing on the market Wednesday
Bluebird Bio stock is flying higher by 20% Monday, following an update of its promising cancer treatments, Jim Cramer said.
The stocks of these two larger-cap biopharma names seem poised to stage comebacks next year.
The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 842,388 share increase in total short interest for BioMarin Pharmaceutical Inc. , to 9,033,035, an increase of 10.28% since 10/31/2017.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.
There are a variety of players that should be active in the M&A space next year.
JJ Bienaime, CEO of orphan drugmaker BioMarin Pharmaceutical, gives Jim Cramer an update on the company's drug portfolio.
Jim Cramer says Washington has, for years, had an inflated view of itself when it comes to passing legislation that helps the economy.
The most recent short interest data has been released for the 09/29/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Evercore ISI analyst Josh Schimmer is bullish on biotech.
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
Big gains could be ahead for investors willing to stick with the stock, according to one firm.
My three top predictions for the next six months.
From Abbott Labs to Wynn, these names rate checking out.
It's a wonder to me how split this market really is.
It's been a heavy week for earnings, but Jim Cramer is already looking ahead to next week -- and Apple.
Brineura is first and only treatment for CLN2 disease, a form of Batten disease.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.